Bleeding pattern, tolerance and patient satisfaction with a drospirenone-containing oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada

Contraception

Volumn 79, Issue 6, 2009, Pages 428-432

  Endrikat, Jan S ^a,b   Milchev, Nikola P ^c   Kapamadzija, Aleksandra ^d   Georgievska, Jadranka ^e   Gerlinger, Christoph ^f   Schmidt, Werner ^b   Feroze, Sleem ^g  

^a Bayer Inc   (Canada)

^b SAARLAND UNIVERSITY   (Germany)

^c Clinic: UMBAL 'StGeorge'   (Bulgaria)

^d Clinic for Gynecology and Obstetrics   (Serbia)

^e University Clinic of Gynecology and Obstetrics   (Macedonia)

^f BAYER PHARMA AG   (Germany)

^g Oakville Menopause Clinic   (Canada)

Author keywords

Bleeding pattern; Drospirenone; Oral contraception; Tolerance

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL;

ADULT; AMENORRHEA; ARTICLE; BLOATING; BREAST TENDERNESS; DEPRESSION; DRUG TOLERABILITY; DYSMENORRHEA; FEMALE; FLUID RETENTION; HUMAN; MAJOR CLINICAL STUDY; MENSTRUATION; OBSERVATIONAL STUDY; OPEN STUDY; ORAL CONTRACEPTION; PATIENT SATISFACTION; PREMENSTRUAL SYNDROME; SIDE EFFECT; VISUAL ANALOG SCALE; WATER RETENTION;

ADOLESCENT; ADULT; ANDROSTENES; CANADA; COHORT STUDIES; CONTRACEPTIVES, ORAL, COMBINED; ETHINYL ESTRADIOL; EUROPE; FEMALE; HUMANS; METRORRHAGIA; MIDDLE EAST; PATIENT SATISFACTION; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 67349137461     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2008.12.007     Document Type: Article

References (20)

1. Huber J., Foidart J.M., Wuttke W., et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 5 (2000) 25-34
2. Parsey K.S., and Pong A. An open-label, multi-centered study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 61 (2000) 105-111
3. Dinger J.C., Heinemann L.A., and Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on Oral Contraceptives based on 142,475 women-years of observation. Contraception 75 (2007) 344-354
4. Muhn P., Krattenmacher R., Beier S., et al. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception 51 (1995) 99-110
5. Foidart J.M., Oelkers W., and Heithecker R. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. A major breakthrough in tomorrow's oral contraception. Gynecol Snapshot 3 (1995) 13-17
6. Fuhrmann U., Krattenmacher R., Slater E.P., and Fritzemeier K.H. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 54 (1996) 243-251
7. Oelkers W., Foidart J.M., Dombrovicz N., et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance and lipid metabolism. J Clin Endocrinol Metab 80 (1995) 1816-1821
8. Oelkers W., Helmerhorst F.M., Wuttke W., et al. Effect of an oral contraceptive containing drospirenone on the renin-aldosterone system in healthy female volunteers. Gynecol Endocrinol 14 (2000) 204-213
9. Hampton R.M., Zhang H.F., Barnowski C., and Wan G.J. Bleeding patterns with monophasic and triphasic low-dose ethinyl estradiol combined oral contraceptives. Contraception 77 (2008) 415-419
10. Foidart J.M., Wuttke W., Bouw G.M., Gerlinger C., and Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 5 (2000) 124-134
11. Creinin M.D., Meyn L.A., Borgatta L., et al. Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial. Obstet Gynecol 111 (2008) 267-277
12. Endrikat J., Düsterberg B., Ruebig A., Gerlinger C., and Strowitzki T. Comparison of efficacy, cycle control and tolerability of two low-dose oral contraceptives containing 20 μg ethinylestradiol/75 μg gestodene and 20 μg ethinylestradiol/150 μg desogestrel in a multicenter clinical study. Contraception 60 (1999) 269-274
13. Moos R.H. The development of a menstrual distress questionnaire. Psychosom Med 30 (1968) 843-867
14. Moos R.H. Menstrual distress questionnaire manual. Western Psychological Services, Los Angeles, CA; 1968.
15. Endrikat J., Sandri M., Gerlinger C., et al. A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 mcg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight. Eur J Contracept Reprod Health Care 12 (2007) 220-228
16. Brown C., Ling F., and Wan J. A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms. J Reprod Med 47 (2002) 14-22
17. Fruzzetti F., Lazzarini V., Ricci C., et al. Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention. Contraception 76 (2007) 190-194
18. Fruzzetti F., Lello S., Lazzarini V., et al. The oral contraceptive containing 30 microg of ethinylestradiol plus 3 mg of drospirenone is able to antagonize the increase of extracellular water occurring in healthy young women during the luteal phase of the menstrual cycle: an observational study. Contraception 75 (2007) 199-203
19. Apter D., Borsos A., Baumgärtner W., et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care 8 (2003) 37-51
20. Borges L.E., Andrade R.P., Aldrighi J.M., et al. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception. Contraception 74 (2006) 446-450